TRIO Clinical Trials in Columbus, Ohio
8 recruitingColumbus, Ohio
Showing 1–8 of 8 trials
Recruiting
Phase 3
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+5 more
National Cancer Institute (NCI)360 enrolled408 locationsNCT05256225
Recruiting
Phase 1
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Recurrent Endometrial CarcinomaRecurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Ovarian Clear Cell Adenocarcinoma+6 more
National Cancer Institute (NCI)65 enrolled14 locationsNCT05950464
Recruiting
Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Recurrent Endometrial CarcinomaEndometrial AdenocarcinomaEndometrial Clear Cell Adenocarcinoma+6 more
National Cancer Institute (NCI)81 enrolled137 locationsNCT05112601
Recruiting
Phase 3
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Ovarian CarcinomaOvarian High Grade Serous AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+6 more
NRG Oncology880 enrolled676 locationsNCT06580314
Recruiting
Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Endometrioid Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer+4 more
Genelux Corporation186 enrolled31 locationsNCT05281471
Recruiting
Early Phase 1
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
Stage III Ovarian Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IIIA Ovarian Cancer AJCC v8+30 more
Ohio State University Comprehensive Cancer Center45 enrolled1 locationNCT05415709
Recruiting
Phase 2
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Endometrioid Ovarian CancerFallopian Tube CancerEpithelial Ovarian Cancer+1 more
TORL Biotherapeutics, LLC230 enrolled66 locationsNCT06690775
Recruiting
Phase 3
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
EndometriosisUterine Fibroids
Sumitomo Pharma Switzerland GmbH1,000 enrolled120 locationsNCT05862272